Alpha Mark Advisors, LLC Enanta Pharmaceuticals Inc Transaction History

Alpha Mark Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 06, 2019	SELL	$65.41 - $84.65 $608,967 - $788,091	-9,310 Closed	0 $0
Q3 2018 Nov 05, 2018	SELL	$85.46 - $126.37 $154,255 - $228,097	-1,805 Reduced 16.24%	9,310 $796,000
Q2 2018 Aug 03, 2018	SELL	$81.85 - $120.51 $294,660 - $433,836	-3,600 Reduced 24.46%	11,115 $1.29 Million
Q1 2018 May 09, 2018	SELL	$57.91 - $92.15 $303,158 - $482,405	-5,235 Reduced 26.24%	14,715 $1.19 Million
Q4 2017 Feb 09, 2018	SELL	$45.65 - $59.37 $253,357 - $329,503	-5,550 Reduced 21.76%	19,950 $1.17 Million
Q3 2017 Nov 02, 2017	BUY	$37.91 - $46.8 $966,704 - $1.19 Million	25,500	25,500 $1.19 Million

109

21.2M

4.8K

4.6K

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $106M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

Get notified when there are updates to the investment portfolio of Alpha Mark Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Mark Advisors, LLC with notifications on news.